"Immunogenicity, Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses.
| Descriptor ID |
D000071497
|
| MeSH Number(s) |
G12.070.500 G12.450.050.370.500 G12.450.050.460 G12.513
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunogenicity, Vaccine".
Below are MeSH descriptors whose meaning is more specific than "Immunogenicity, Vaccine".
This graph shows the total number of publications written about "Immunogenicity, Vaccine" by people in this website by year, and whether "Immunogenicity, Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 6 | 10 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 4 | 6 |
| 2022 | 2 | 4 | 6 |
| 2023 | 1 | 6 | 7 |
| 2024 | 2 | 5 | 7 |
| 2025 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunogenicity, Vaccine" by people in Profiles.
-
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections. Nat Immunol. 2025 Jun; 26(6):829-836.
-
Safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 18; 22(1):56.
-
Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis. Reprod Health. 2025 Apr 15; 22(1):53.
-
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone? or Flublok?) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45?years of age. Vaccine. 2025 Apr 30; 54:126991.
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
-
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. J Infect Dis. 2025 Feb 04; 231(1):e123-e131.
-
Immunogenicity of COVID-19 Vaccines During Pregnancy: A Systematic Review and Comparison of Pregnant Versus Nonpregnant Persons. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S27-S31.
-
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
-
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.